Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures
Phase of Trial: Phase IV
Latest Information Update: 30 May 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Generalised seizures; Partial epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Korea
- 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
- 24 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
- 12 May 2016 Status changed from not yet recruiting to recruiting.